← All trials
NCT00000488
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 1973
- Primary completion
- —
- Completion date
- Oct 1, 1989
- First posted
- —
- Last posted
- —
- Enrollment
- —
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- National Heart, Lung, and Blood Institute (NHLBI)Lead sponsor
- University of IowaOfficial
- University of California, San DiegoOfficial
- Oklahoma Medical Research FoundationOfficial
- Stanford UniversityOfficial
- University of WashingtonOfficial
- Johns Hopkins UniversityOfficial
- University of TorontoOfficial
- University of CincinnatiOfficial
- University of MinnesotaOfficial
- Bio-Science LaboratoriesOfficial
- George Washington UniversityOfficial
- Baylor UniversityOfficial
- Washington University in St. LouisOfficial
- University of Alabama, BirminghamOfficial
- Centers for Disease Control and Prevention (CDC)Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.